204 related articles for article (PubMed ID: 1677419)
1. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons.
Crowe SM; Carlin JB; Stewart KI; Lucas CR; Hoy JF
J Acquir Immune Defic Syndr (1988); 1991; 4(8):770-6. PubMed ID: 1677419
[TBL] [Abstract][Full Text] [Related]
2. [CD4+ lymphocytes and opportunistic infections and neoplasms in patients with human immunodeficiency virus infection].
Miró JM; Buira E; Mallolas J; Gallart T; Moreno A; Zamora L; Vilella R; Gatell JM; Soriano E
Med Clin (Barc); 1994 Apr; 102(15):566-70. PubMed ID: 7646597
[TBL] [Abstract][Full Text] [Related]
3. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
4. Natural history of opportunistic disease in an HIV-infected urban clinical cohort.
Moore RD; Chaisson RE
Ann Intern Med; 1996 Apr; 124(7):633-42. PubMed ID: 8607591
[TBL] [Abstract][Full Text] [Related]
5. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991.
Muñoz A; Schrager LK; Bacellar H; Speizer I; Vermund SH; Detels R; Saah AJ; Kingsley LA; Seminara D; Phair JP
Am J Epidemiol; 1993 Feb; 137(4):423-38. PubMed ID: 8096356
[TBL] [Abstract][Full Text] [Related]
6. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.
Mocroft A; Sabin CA; Youle M; Madge S; Tyrer M; Devereux H; Deayton J; Dykhoff A; Lipman MC; Phillips AN; Johnson MA
J Acquir Immune Defic Syndr; 1999 Aug; 21(5):401-7. PubMed ID: 10458621
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of disease in persons with human immunodeficiency virus infection in the United States.
Farizo KM; Buehler JW; Chamberland ME; Whyte BM; Froelicher ES; Hopkins SG; Reed CM; Mokotoff ED; Cohn DL; Troxler S
JAMA; 1992 Apr; 267(13):1798-805. PubMed ID: 1347573
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
[TBL] [Abstract][Full Text] [Related]
9. HIV infection and AIDS.
Lloyd A
P N G Med J; 1996 Sep; 39(3):174-80. PubMed ID: 9795558
[TBL] [Abstract][Full Text] [Related]
10. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection.
Masur H; Ognibene FP; Yarchoan R; Shelhamer JH; Baird BF; Travis W; Suffredini AF; Deyton L; Kovacs JA; Falloon J
Ann Intern Med; 1989 Aug; 111(3):223-31. PubMed ID: 2546472
[TBL] [Abstract][Full Text] [Related]
11. Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort.
Dore GJ; Hoy JF; Mallal SA; Li Y; Mijch AM; French MA; Cooper DA; Kaldor JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):39-43. PubMed ID: 9377123
[TBL] [Abstract][Full Text] [Related]
12. Impact of opportunistic disease on survival in patients with HIV infection.
Chaisson RE; Gallant JE; Keruly JC; Moore RD
AIDS; 1998 Jan; 12(1):29-33. PubMed ID: 9456252
[TBL] [Abstract][Full Text] [Related]
13. The Western Australian HIV Cohort Study, Perth, Australia.
Mallal SA
J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 17 Suppl 1():S23-7. PubMed ID: 9586648
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients.
Antinori A; Izzi I; Ammassari A; Camilli G; Murri R; Tamburrini E
J Cancer Res Clin Oncol; 1992; 118(8):635-6. PubMed ID: 1355486
[TBL] [Abstract][Full Text] [Related]
15. Hierarchical pattern of mucosal candida infections in HIV-seropositive women.
Imam N; Carpenter CC; Mayer KH; Fisher A; Stein M; Danforth SB
Am J Med; 1990 Aug; 89(2):142-6. PubMed ID: 1974383
[TBL] [Abstract][Full Text] [Related]
16. HIV infection/acquired immunodeficiency syndrome at Siriraj Hospital, 2002: time for secondary prevention.
Anekthananon T; Ratanasuwan W; Techasathit W; Rongrungruang Y; Suwanagool S
J Med Assoc Thai; 2004 Feb; 87(2):173-9. PubMed ID: 15061301
[TBL] [Abstract][Full Text] [Related]
17. Risk of cancers during interrupted antiretroviral therapy in the SMART study.
Silverberg MJ; Neuhaus J; Bower M; Gey D; Hatzakis A; Henry K; Hidalgo J; Lourtau L; Neaton JD; Tambussi G; Abrams DI
AIDS; 2007 Sep; 21(14):1957-63. PubMed ID: 17721103
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma.
Fischl MA; Uttamchandani RB; Resnick L; Agarwal R; Fletcher MA; Patrone-Reese J; Dearmas L; Chidekel J; McCann M; Myers M
J Acquir Immune Defic Syndr (1988); 1991; 4(1):1-10. PubMed ID: 1670585
[TBL] [Abstract][Full Text] [Related]
19. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
Renwick N; Halaby T; Weverling GJ; Dukers NH; Simpson GR; Coutinho RA; Lange JM; Schulz TF; Goudsmit J
AIDS; 1998 Dec; 12(18):2481-8. PubMed ID: 9875587
[TBL] [Abstract][Full Text] [Related]
20. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
